Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation[1].
On CASMCs induced by phenylephrine, isoliensinine has an antiproliferative effect. Its mechanisms involve reducing the overexpression of growth factors (PDGF-beta, bFGF), protooncogenes (c-fos, c-myc), and hsp70[3]. |
---|---|
ln Vitro |
Isoliensinine promotes apoptosis in triple-negative human breast cancer cells through ROS production and p38 MAPK/JNK activation [1]. Isorisinine has an anti-proliferative effect on phenylephrine-induced CASMCs, and its mechanism is connected to lowering the overexpression of growth factors (PDGF-β, bFGF), proto-oncogenes (c-fos, c-myc) and hsp70[3].
|
References |
[1]. Jun-hua Xiao, et al. Effects of isoliensinine on proliferation of porcine coronary arterial smooth muscle cells induced by phenylephrine. Yao Xue Xue Bao. 2005 Feb;40(2):105-10.
[2]. Zhang X, et al. Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation. Sci Rep. 2015 Jul 29;5:12579. [3]. Xiao JH, et al. Effects of isoliensinine on proliferation of porcine coronary arterial smooth muscle cells induced by phenylephrine. Yao Xue Xue Bao. 2005 Feb;40(2):105-10. |
Molecular Formula |
C37H42N2O6
|
---|---|
Molecular Weight |
610.7392
|
Exact Mass |
610.30428706
|
CAS # |
6817-41-0
|
Related CAS # |
6817-41-0
|
Appearance |
Solid
|
SMILES |
CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)O)O)OC
|
InChi Key |
AJPXZTKPPINUKN-FIRIVFDPSA-N
|
InChi Code |
InChI=1S/C37H42N2O6/c1-38-15-13-26-20-36(44-5)37(22-29(26)30(38)16-23-6-9-27(42-3)10-7-23)45-35-18-24(8-11-32(35)40)17-31-28-21-33(41)34(43-4)19-25(28)12-14-39(31)2/h6-11,18-22,30-31,40-41H,12-17H2,1-5H3/t30-,31-/m1/s1
|
Chemical Name |
(1R)-1-[[4-hydroxy-3-[[(1R)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl]oxy]phenyl]methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol
|
Synonyms |
Isoliensinine
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 50~100 mg/mL(81.9~163.7 mM)
Ethanol: ~100 mg/mL(~163.7 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.6374 mL | 8.1868 mL | 16.3736 mL | |
5 mM | 0.3275 mL | 1.6374 mL | 3.2747 mL | |
10 mM | 0.1637 mL | 0.8187 mL | 1.6374 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effect of isoliensinine on growth in human breast cancer cells and normal human breast epithelial cells. Sci Rep . 2015 Jul 29:5:12579. td> |
Effect of isoliensinine on cell cycle distribution in MDA-MB-231 cells and normal human breast epithelial cells. Sci Rep . 2015 Jul 29:5:12579. td> |
Pro-apoptotic effect of isoliensinine on triple-negative breast cancer cells. Sci Rep . 2015 Jul 29:5:12579. td> |
The accumulation of ROS production is required for apoptosis induced by isoliensinine in triple-negative breast cancer cells. Sci Rep . 2015 Jul 29:5:12579. td> |
p38 MAPK and JNK pathways mediate isoliensinine-induced apoptosis in triple-negative breast cancer cells. Sci Rep . 2015 Jul 29:5:12579. td> |
Effect of p38 MAPK and JNK inhibition on isoliensinine-induced ROS generation. Sci Rep . 2015 Jul 29:5:12579. td> |